Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Magna Pharmaceuticals, Inc
WARNING LETTER
•Magna Pharmaceuticals, Inc•December 31, 2009

Magna Pharmaceuticals, Inc – FDA Warning Letter, Dec 31, 2009

Record Details

This FDA Warning Letter, issued to Magna Pharmaceuticals, Inc., addresses violations related to unapproved and misbranded drug products. The letter follows an earlier warning to (b)(4), a manufacturer with whom Magna Pharmaceuticals contracted. Specifically, the firm distributes Ahist Tablets (Chlorpheniramine Tannate), which are deemed "new drugs" under section 201(p) of the Act because they are not generally recognized as safe and effective. There is no FDA-approved application for this drug product, violating sections 301(d) and 505(a) of the Act. Consequently, the introduction of this product into interstate commerce without an approved new drug application violates sections 301(a) and (d). Additionally, the product is misbranded under section 502(f)(1) because its labeling lacks adequate directions for use, as it is intended for conditions not amenable to self-diagnosis (21 C.F.R. § 201.5). The drug product is also cited as adulterated under 21 U.S.C. 351(a)(2)(B). Magna Pharmaceuticals is responsible for investigating and correcting these violations promptly. Failure to do so may result in legal action, including seizure and injunction, and may impact the firm's eligibility for federal contracts. A written response detailing corrective actions and prevention measures is required within fifteen working days.

Company
Magna Pharmaceuticals, Inc
Inspection date
December 31, 2009
Product type
Drugs
Office
Cincinnati District Office
Person
  • Teresa C. Thompson
View Company Profile

ID · 572166ff-6156-45dd-ba2a-499faf526181

Violation Codes9
21 U.S.C. 321(g)21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 355(b)21 CFR 201.521 CFR 201.115

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Magna Pharmaceuticals, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.